Fortress Biotech, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Fortress Biotech significantly reduced its net loss in 2025, driven by strategic asset monetizations and product approvals, despite ongoing operating losses and a paused preferred stock dividend.
NASDAQ
10-K: Fortress Biotech Reports 2024 Results, Highlights UNLOXCYT Approval and Checkpoint Acquisition
Fortress Biotech's 2024 10-K filing details financial results, key developments including UNLOXCYT approval, and the pending acquisition of Checkpoint Therapeutics.
NASDAQ
Fortress Biotech's 10-K filing provides a detailed overview of its capital stock, preferred stock, outstanding warrants, and various employee stock programs.